LifeVantage Corporation (Nasdaq: LFVN), a health and wellness company focused on products that support cellular health, has reported its financial results for the quarter ended September 30, 2026.
Revenue for the first quarter of fiscal 2027 was $37.1 million, a 22.0% decrease from the prior-year period. Revenue in the Americas declined 22.2%, while revenue in Asia/Pacific & Europe fell 21.2%.
Net loss per diluted share was $0.02, compared to net income of $0.17 per diluted share a year earlier. Adjusted earnings per diluted share came in at $0.05, versus $0.18 in the same quarter last year. Adjusted EBITDA was $1.9 million, down from $3.9 million.
Terrence Moorehead, President and Chief Executive Officer, addressed the results:
“Despite a challenging quarter, LifeVantage has significant untapped potential, and we now have a clear strategy designed to capture it.Â
Our focus is on transforming LifeVantage into a more brand-driven, consumer-focused company, supported by a modern digital platform and an expanding community of consumers and brand advocates. At the same time, we are creating a more focused and efficient operating model and strengthening the underlying economics of the business. We have a lot of work to do, and building the company we envision will take time, but we have a differentiated foundation, a clear roadmap and a strong sense of urgency around execution. The actions we are taking are designed to build a stronger, more relevant LifeVantage and create sustainable long-term value for our shareholders.”
Revenue of $37.1 million compared to $47.6 million in the prior-year quarter, including a $0.4 million negative impact from foreign currency. The decline was driven primarily by lower active accounts and reduced sales of the MindBody GLP-1 System. These factors were partially offset by sales from the LoveBiome product line, which the company acquired in October 2025.
Gross profit was $28.0 million, or 75.4% of revenue, compared to $37.8 million, or 79.5%, a year earlier. The lower margin reflected an inventory obsolescence allowance related to the MindBody GLP-1 System and higher shipping and warehouse costs. Adjusted non-GAAP gross profit was $29.0 million, or 78.2% of revenue.
Commissions and incentives expense decreased to $15.4 million (41.4% of revenue) from $20.7 million (43.5%). Selling, general and administrative expenses were $12.7 million, or 34.3% of revenue, compared to $14.9 million, or 31.2%, in the prior year.
Operating loss was $0.1 million, versus operating income of $2.3 million a year ago. Adjusted non-GAAP operating income was $0.9 million. Net loss was $0.2 million, or $0.02 per diluted share. Adjusted non-GAAP net income was $0.6 million, or $0.05 per diluted share. Adjusted EBITDA stood at $1.9 million, or 5.2% of revenue.
The company generated $0.5 million in cash from operations during the quarter, compared to $2.3 million used in the prior-year period. Cash and cash equivalents totaled $13.7 million as of September 30, 2026, with no debt outstanding. No shares were repurchased during the quarter, leaving $58.5 million remaining under the existing $60 million share repurchase program.
LifeVantage Corporation (Nasdaq: LFVN) is a pioneer in nutrigenomics, the study of how nutrition and naturally occurring compounds can influence gene expression and cellular health. Its product portfolio includes the Protandim family of products, TrueScience Liquid Collagen, the MindBody GLP-1 System, LoveBiome P84, AXIO energy drink mixes, TrueScience skin and hair care products, and Petandim for dogs. Independent Consultants sell the products and share the business opportunity. The company was founded in 2003 and is headquartered in Lehi, Utah. More information is available at
There are no reviews yet. Be the first one to write one.
